Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations

Alnylam Pharmaceuticals (NASDAQ:ALNY) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$773.7m (up 17% from 2Q 2024).
• Net loss: US$66.3m (loss widened by 292% from 2Q 2024).
• US$0.51 loss per share (further deteriorated from US$0.13 loss in 2Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Alnylam Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 27%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 29% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Alnylam Pharmaceuticals' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.